MessageGears, the leading data activation and engagement platform for enterprise brands, today announced it has been recognized as a Validated Partner of Databricks, the data and AI company. The ...

ACI Worldwide , an original innovator in global payments technology, has been recognized among leading solutions providers in Datos Insights' latest report on the fraud orchestration solutions market, ...

Ciara Freeman, MD, PhD, discusses the challenges of incorporating anito-cel into the treatment protocol for patients with multiple myeloma.

Reported Net Product Revenues of $20.9 million for the first quarter of 2025, a year-over-year increase of approximately 8% National Comprehensive Cancer Network® (NCCN®) Clinical Practice Guidelines ...

CARVYKTI® (ciltacabtagene autoleucel; cilta-cel) net trade sales of approximately $369 millionOver 6,000 patients treated to ...

On May 7, 2025, Y-mAbs announced that naxitamab-gqgk (DANYELZA ®) has been recommended by the National Comprehensive Cancer Network ® ("NCCN”) Clinical Practice Guidelines in Oncology (NCCN Guidelines ...

US biotech IGM Biosciences (Nasdaq: IGMS), which is developing and delivering medicines to treat patients with autoimmune and ...

多发性骨髓瘤（MM）复发问题严峻，尤其在经多线治疗后。研究人员开展他雷妥单抗（talquetamab）治疗日本复发 / 难治性 MM 的 1 期研究。结果显示其安全性可接受，疗效良好，为日本 RRMM 患者带来新选择。

Johnson & Johnson has generated evidence that the pace of oncology innovation is overwhelming physicians. | Johnson & Johnson ...

Y-mAbs Therapeutics, Inc.’s YMAB share price has dipped by 5.65%, which has investors questioning if this is right time to ...

Glenmark's cancer drug ISB 2001 gets fast track designation from US FDA: Our Bureau, New Delhi Tuesday, May 6, 2025, 11:15 Hrs [IST] New York-based Ichnos Glenmark Innovation (IGI ...

Glenmark Pharma's innovation arm, IGI, received FDA fast track designation for its myeloma therapy ISB 2001, targeting ...